+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Proprotein Convertase Subtilisin/kexin Type 9 Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

  • Report

  • 300 Pages
  • December 2023
  • Region: Global
  • Infinium Global Research
  • ID: 5557575
The report on the global proprotein convertase subtilisin/kexin type 9 market provides qualitative and quantitative analysis for the period from 2021-2030. The global proprotein convertase subtilisin/kexin type 9 market was valued at USD 2.46 billion in 2022 and is expected to reach USD 5.09 billion in 2030, with a CAGR of 9.56% during the forecast period 2023-2030. The study on proprotein convertase subtilisin/kexin type 9 market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.

The report on proprotein convertase subtilisin/kexin type 9 market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global proprotein convertase subtilisin/kexin type 9 market over the period of 2021-2030. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global proprotein convertase subtilisin/kexin type 9 market over the period of 2021-2030. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

  • The proprotein convertase subtilisin/kexin type 9 market is driven by rising cardiovascular disease concerns.
  • The clinical effectiveness and high efficacy of proprotein convertase subtilisin/kexin type 9 fuels the market growth.

2) Restraints

  • High cost and accessibility factors of these inhibitors can act as a barrier to market growth.

3) Opportunities

  • The evolving research landscape and ongoing clinical trials present a significant opportunity for pcsk9 inhibitors.

Research Methodology

A) Primary Research

The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders associated
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered

The global proprotein convertase subtilisin/kexin type 9 market is segmented on the basis of product, and application.

The Global Proprotein Convertase Subtilisin/Kexin Type 9 Market by Product

  • SX-PCK9
  • K-312
  • LY3015014
  • Others

The Global Proprotein Convertase Subtilisin/Kexin Type 9 Market by Application

  • Cardiovascular Disease
  • Homozygous Familial Hypercholesterolaemia
  • Liver Disease
  • Metabolic Syndrome
  • Others

Company Profiles

The companies covered in the report include
  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Ensemble Therapeutics Corporation
  • Alnylam Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals Inc.
  • AFFiRiS AG
  • Merck & Co., Inc.
  • Sanofi
  • AstraZeneca

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the proprotein convertase subtilisin/kexin type 9 market.
2. Complete coverage of all the segments in the proprotein convertase subtilisin/kexin type 9 market to analyze the trends, developments in the global market and forecast of market size up to 2030.
3. Comprehensive analysis of the companies operating in the global proprotein convertase subtilisin/kexin type 9 market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

This product will be delivered within 1-3 business days.

Frequently Asked Questions about the Global Proprotein Convertase Subtilisin/kexin Type 9 Market

What is the estimated value of the Global Proprotein Convertase Subtilisin/kexin Type 9 Market?

The Global Proprotein Convertase Subtilisin/kexin Type 9 Market was estimated to be valued at $2.46 Billion in 2022.

What is the growth rate of the Global Proprotein Convertase Subtilisin/kexin Type 9 Market?

The growth rate of the Global Proprotein Convertase Subtilisin/kexin Type 9 Market is 9.5%, with an estimated value of $5.09 Billion by 2030.

What is the forecasted size of the Global Proprotein Convertase Subtilisin/kexin Type 9 Market?

The Global Proprotein Convertase Subtilisin/kexin Type 9 Market is estimated to be worth $5.09 Billion by 2030.

Who are the key companies in the Global Proprotein Convertase Subtilisin/kexin Type 9 Market?

Key companies in the Global Proprotein Convertase Subtilisin/kexin Type 9 Market include Amgen Inc., Novartis AG, Eli Lilly and Company, Ensemble Therapeutics Corporation, Alnylam Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., AFFiRiS AG, Merck & Co., Inc., Sanofi and AstraZeneca.

Table of Contents

Chapter 1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
Chapter 2. Executive Summary
2.1. Proprotein Convertase Subtilisin/kexin Type 9 Market Highlights
2.2. Proprotein Convertase Subtilisin/kexin Type 9 Market Projection
2.3. Proprotein Convertase Subtilisin/kexin Type 9 Market Regional Highlights
Chapter 3. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Product
3.4.2. Growth Matrix Analysis by Application
3.4.3. Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Proprotein Convertase Subtilisin/kexin Type 9 Market
Chapter 4. Proprotein Convertase Subtilisin/kexin Type 9 Market Macro Indicator Analysis
Chapter 5. Company Profiles and Competitive Landscape
5.1. Competitive Landscape in the Global Proprotein Convertase Subtilisin/kexin Type 9 Market
5.2. Companies Profiles
5.2.1. Amgen Inc.
5.2.2. Novartis AG
5.2.3. Eli Lilly and Company
5.2.4. Ensemble Therapeutics Corporation
5.2.5. Alnylam Pharmaceuticals, Inc.
5.2.6. Regeneron Pharmaceuticals Inc.
5.2.7. AFFiRiS AG
5.2.8. Merck & Co., Inc.
5.2.9. Sanofi
5.2.10. AstraZeneca
Chapter 6. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market by Product
6.1. SX-PCK9
6.2. K-312
6.3. LY3015014
6.4. Others
Chapter 7. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market by Application
7.1. Cardiovascular Disease
7.2. Homozygous Familial Hypercholesterolaemia
7.3. Liver Disease
7.4. Metabolic Syndrome
7.5. Others
Chapter 8. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market by Region 2023-2030
8.1. North America
8.1.1. North America Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.1.2. North America Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.1.3. North America Proprotein Convertase Subtilisin/kexin Type 9 Market by Country
8.1.3.1. The U.S. Proprotein Convertase Subtilisin/kexin Type 9 Market
8.1.3.1.1. The U.S. Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.1.3.1.2. The U.S. Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.1.3.2. Canada Proprotein Convertase Subtilisin/kexin Type 9 Market
8.1.3.2.1. Canada Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.1.3.2.2. Canada Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.1.3.3. Mexico Proprotein Convertase Subtilisin/kexin Type 9 Market
8.1.3.3.1. Mexico Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.1.3.3.2. Mexico Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.2. Europe
8.2.1. Europe Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.2.2. Europe Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.2.3. Europe Proprotein Convertase Subtilisin/kexin Type 9 Market by Country
8.2.3.1. Germany Proprotein Convertase Subtilisin/kexin Type 9 Market
8.2.3.1.1. Germany Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.2.3.1.2. Germany Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.2.3.2. United Kingdom Proprotein Convertase Subtilisin/kexin Type 9 Market
8.2.3.2.1. United Kingdom Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.2.3.2.2. United Kingdom Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.2.3.3. France Proprotein Convertase Subtilisin/kexin Type 9 Market
8.2.3.3.1. France Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.2.3.3.2. France Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.2.3.4. Italy Proprotein Convertase Subtilisin/kexin Type 9 Market
8.2.3.4.1. Italy Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.2.3.4.2. Italy Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.2.3.5. Rest of Europe Proprotein Convertase Subtilisin/kexin Type 9 Market
8.2.3.5.1. Rest of Europe Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.2.3.5.2. Rest of Europe Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.3. Asia Pacific
8.3.1. Asia Pacific Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.3.2. Asia Pacific Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.3.3. Asia Pacific Proprotein Convertase Subtilisin/kexin Type 9 Market by Country
8.3.3.1. China Proprotein Convertase Subtilisin/kexin Type 9 Market
8.3.3.1.1. China Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.3.3.1.2. China Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.3.3.2. Japan Proprotein Convertase Subtilisin/kexin Type 9 Market
8.3.3.2.1. Japan Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.3.3.2.2. Japan Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.3.3.3. India Proprotein Convertase Subtilisin/kexin Type 9 Market
8.3.3.3.1. India Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.3.3.3.2. India Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.3.3.4. South Korea Proprotein Convertase Subtilisin/kexin Type 9 Market
8.3.3.4.1. South Korea Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.3.3.4.2. South Korea Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.3.3.5. Australia Proprotein Convertase Subtilisin/kexin Type 9 Market
8.3.3.5.1. Australia Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.3.3.5.2. Australia Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.3.3.6. Rest of Asia-Pacific Proprotein Convertase Subtilisin/kexin Type 9 Market
8.3.3.6.1. Rest of Asia-Pacific Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.3.3.6.2. Rest of Asia-Pacific Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.4. RoW
8.4.1. RoW Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.4.2. RoW Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.4.3. RoW Proprotein Convertase Subtilisin/kexin Type 9 Market by Sub-region
8.4.3.1. Latin America Proprotein Convertase Subtilisin/kexin Type 9 Market
8.4.3.1.1. Latin America Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.4.3.1.2. Latin America Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.4.3.2. Middle East Proprotein Convertase Subtilisin/kexin Type 9 Market
8.4.3.2.1. Middle East Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.4.3.2.2. Middle East Proprotein Convertase Subtilisin/kexin Type 9 Market by Application
8.4.3.3. Africa Proprotein Convertase Subtilisin/kexin Type 9 Market
8.4.3.3.1. Africa Proprotein Convertase Subtilisin/kexin Type 9 Market by Product
8.4.3.3.2. Africa Proprotein Convertase Subtilisin/kexin Type 9 Market by Application

Companies Mentioned

  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Ensemble Therapeutics Corporation
  • Alnylam Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals Inc.
  • AFFiRiS AG
  • Merck & Co., Inc.
  • Sanofi
  • AstraZeneca